Benefit of early commencement of growth hormone therapy in children with Prader-Willi syndrome

Nyunt, O., Harris, M., Hughes, I., Huynh, T., Davies, P. S. W. and Cotterill, A. M. (2009) Benefit of early commencement of growth hormone therapy in children with Prader-Willi syndrome. Journal of Pediatric Endocrinology and Metabolism, 22 12: 1151-1158.

Attached Files (Some files may be inaccessible until you login with your UQ eSpace credentials)
Name Description MIMEType Size Downloads
UQ200092_OA.pdf Full text (open access) application/pdf 1.03MB 0
Author Nyunt, O.
Harris, M.
Hughes, I.
Huynh, T.
Davies, P. S. W.
Cotterill, A. M.
Title Benefit of early commencement of growth hormone therapy in children with Prader-Willi syndrome
Journal name Journal of Pediatric Endocrinology and Metabolism   Check publisher's open access policy
ISSN 0334-018X
2191-0251
Publication date 2009-12
Year available 2009
Sub-type Article (original research)
Open Access Status File (Publisher version)
Volume 22
Issue 12
Start page 1151
End page 1158
Total pages 8
Place of publication London, U.K.
Publisher Freund; Walter de Gruyter
Language eng
Subject 1114 Paediatrics and Reproductive Medicine
C1
Formatted abstract
Prader-Willi syndrome (PWS) is a chromosomal disorder and growth failure is a common presentation. Growth hormone (GH) treatment is beneficial in PWS although the optimal age for starting GH is unknown. We investigated whether GH response in PWS was associated with the age of GH commencement by comparing 16 children who commenced GH before 3 years of age (early group) with 40 children who commenced GH after 3 years of age (late group) from the Ozgrow database. Height SDS, body mass index (BMI) SDS, bone age (BA)-chronological age (CA) ratio, change in height (Δ Ht) SDS and change in BMI during 4 years of GH treatment were compared between the groups. The early group had better height SDS and Δ Ht SDS. BA delay was more pronounced in the early group but BA did not mature beyond CA with GH therapy in either group. Although the initial GH dose for the early group was lower than that of the late group, the former had better height outcome. The starting GH dose seen in the database is lower than the dose used by international centres.
Keyword Prader-Willi syndrome
PWS
Growth hormone
GH
Benefit
Ozgrow
Q-Index Code C1
Q-Index Status Provisional Code

Document type: Journal Article
Sub-type: Article (original research)
Collection: School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 4 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 0 times in Scopus Article
Google Scholar Search Google Scholar
Created: Sun, 21 Mar 2010, 00:04:52 EST